SFP
ALNY icon

Shepherd Financial Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Shepherd Financial Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$825K Buy
2,741
+5
+0.2% +$1.51K 0.07% 132
2026
Q1 		$905K Hold
2,736
– – 0.09% 120
2025
Q4 		$1.09M Hold
2,736
– – 0.1% 110
2025
Q3 		$1.25M Hold
2,736
– – 0.12% 103
2025
Q2 		$892K Hold
2,736
– – 0.09% 113
2025
Q1 		$739K Hold
2,736
– – 0.09% 129
2024
Q4 		$644K Hold
2,736
– – 0.08% 124
2024
Q3 		$752K Buy
+2,736
New +$712K 0.09% 116

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Shepherd Financial Partners's ALNY Position: Q2 2026 in Review

Shepherd Financial Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 0.18% in Q2 2026, buying an estimated $1.51K and bringing the position to 2,741 shares worth $825K. The position accounts for 0.07% of the portfolio, ranked #132.

Shepherd Financial Partners first reported a position in ALNY in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.25M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Shepherd Financial Partners held 2,741 shares of Alnylam Pharmaceuticals worth $825K as of Q2 2026.
  • Shepherd Financial Partners bought 5 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.51K.
  • Alnylam Pharmaceuticals made up 0.07% of Shepherd Financial Partners's portfolio in Q2 2026, its #132 holding.
  • Shepherd Financial Partners first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Shepherd Financial Partners's Alnylam Pharmaceuticals position peaked at $1.25M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Shepherd Financial Partners's 13F filing for Q2 2026, filed 10 Aug 2026.